¶¶Òõ¶ÌÊÓƵ

From Edit to IND: Clarity, Safety, and Speed with INDUCE-seq

±õ±·¶Ù±«°ä·¡-²õ±ð±ç® is an assay and analysis platform purpose-built to support the preclinical development of gene editing therapies and gene-edited cell therapies. By delivering high-resolution, PCR-free mapping of double-strand DNA breaks, it enables rigorous, unbiased evaluation of both on-target and off-target gene editing events simultaneously, accelerating the advancement of safe advanced therapies toward IND submission.

During the IND-enabling phase, INDUCE-seq provides:

• Quantitative Assessment of On-Target Editing
  Precisely measure and characterize the mechanism of editing across established and novel editing systems to validate consistency, efficacy, and performance of lead candidates.
• Rapid and Highly Sensitive Detection of Off-Target Events
  Identify unintended induced breaks at single-nucleotide resolution to mitigate safety risks and strengthen regulatory submissions. Accelerate program progression with critical readouts on editing specificity generated in days.
• Comparative Evaluation of Editing Strategies
  Compare editing systems, delivery methods, or guide RNAs to select the most specific and clinically viable approach.
• A Cell and Editor Agnostic Platform
  INDUCE-seq evaluates gene editing safety across all cell types, including patient-derived cells, iPSCs, neuronal cells, and T cells. Reveals unintended breaks induced by any gene editing system including nucleases, base editors, and novel editing modalities. 
• Guide Optimization and Safety Screening
  Optimize guide RNA design by analyzing off-target activity, enabling the early elimination of high-risk candidates.

INDUCE-seq helps developers de-risk gene-edited therapeutics, streamline preclinical decision-making, and build the robust datasets needed to support successful IND filings.